Trial launches, interim results, approvals, safety signals, and what they may mean for patients.
FDA’s accelerated approval of teplizumab (Tzield) for certain children with recently diagnosed stage 3 type 1 diabetes raises an urgent caregiver question: what did the key trial actually show, what risks come with treatment, and what still isn’t proven yet?
A new phase 3 trial suggests perioperative apalutamide plus hormone therapy may help some surgery candidates with high-risk prostate cancer, but the regimen is off-label in the United States and not a blanket recommendation.
The FDA is pressing more than 2,200 sponsors and researchers to post required clinical trial results to ClinicalTrials.gov. For patients and readers, the issue is simple: missing results can distort what we think works, what does not, and how safe a medical product really is.
The FDA is pressing sponsors and researchers to report clinical trial results on time, saying missing data can distort what doctors and patients think they know. A new FDA push and an NIH policy update are raising the stakes for transparency as the clinical-trials system evolves.
The FDA is testing a faster way to view some trial data as studies are running while also pressing sponsors to catch up on overdue results reports. The big takeaway for readers: this is a change in transparency and timing, not proof that a therapy works.
A new NIH-backed clinical trial suggests the answer may be yes. In federally qualified health centers, a care model built around home monitoring, coaching, and faster medication adjustments lowered blood pressure more than enhanced usual care over 18 months — but it is a care strategy, not a new drug, and questions remain about cost, scale, and long-term outcomes.
The FDA says it has started two proof-of-concept clinical trials that will send some endpoints and data signals to the agency in real time. The agency is also asking for input on a pilot program that could begin this summer. For readers, the big question is not whether trial oversight is changing today, but whether this early test can improve safety monitoring without adding confusion or weakening transparency.
The FDA has reminded more than 2,200 sponsors and researchers to submit overdue clinical trial results. For patients and clinicians, the issue is not just paperwork: missing results can leave the public record incomplete and make it harder to judge how well a treatment worked, or how safe it looked.
The FDA has accepted a filing to expand Gazyva for systemic lupus erythematosus, but the IV drug is not approved for broader lupus in the U.S. yet.
A randomized trial found methotrexate did not meaningfully improve inflammatory knee osteoarthritis, underscoring that proven knee OA care still matters most.
A randomized trial in community health centers found that team-based support plus home blood pressure checks improved systolic pressure more than enhanced usual care.
FDA approved Icotyde on March 17, 2026, giving some adults and teens with moderate to severe plaque psoriasis a new once-daily pill option.
The FDA approved daily obesity pill orforglipron on April 1. Here is what its main placebo-controlled trial found, and what patients still do not know.
An NIH-backed 20-year follow-up links one specific speed-training program—not all brain games—to fewer dementia diagnoses. Here’s what it means.
A new trial found less clinically important bleeding with apixaban than rivaroxaban after a serious clot, but treatment changes still need a clinician.
Two February 2026 cholesterol headlines show how to judge study design, real outcomes, and official guidance before changing a medicine or screening plan.
A January 2026 follow-up study suggests one year of abatacept may delay rheumatoid arthritis in a narrowly defined high-risk group, but it did not prove permanent prevention or create a new plan for everyday joint aches.
NIH says it is developing a policy framework that could make plain-language study-result summaries more routine for people in NIH-funded clinical research. Here’s what that could mean, what is still only proposed, and what patients should ask before joining a trial.
A large new randomized trial found that spinal manipulation by itself did not significantly outperform guideline-based medical care for pain or disability over 1 year in adults with acute or subacute low back pain at higher risk of long-term problems. Here’s what that means for chiropractic care, self-management, and when back pain needs prompt medical evaluation.
A newly published New England Journal of Medicine trial adds stronger evidence behind Ajovy for some children and teens with episodic migraine. The study found modest average benefit, not a cure, and the current U.S. label applies only to patients ages 6 to 17 who weigh 45 kg or more.
The FDA has approved Nuzolvence, an oral form of zoliflodacin, for some uncomplicated gonorrhea cases. Here is what the phase 3 trial found, what noninferior means, and why this does not apply to every gonorrhea infection.
A new NCCIH consumer update and a large recent JAMA trial point in the same direction: spinal manipulation may help some people with low back pain, but average benefits are usually small, and it works best as one part of a broader plan built around movement, exercise, and self-management.
End of content
End of content